: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Tec

Technologies Reports Second Quarter Fiscal 2010 Financial Results

BRUNSWICK, N.J. (February 17, 2010) - Senesco Technologies, Inc.

("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results

for the three months ended December 31, 2009.

for the three month period ended December 31, 2009 was $1,703,665 or $0.06 per

share, compared with a net loss of $1,624,341, or $0.09 per share, for the three

month period ended December 31, 2008. This increase in net loss was

primarily the result of an increase in non-cash expenses associated with the

outstanding convertible notes, which was mostly offset by a decrease in

operating expenses, an increase in revenue and an increase in non-cash income

related to the change in fair value of a warrant liability.

and Recent Highlights

top priorities in 2010 are to attract sufficient financing and file an IND for

SNS-01, our multiple myeloma drug candidate," said Jack Van Hulst, President and

Chief Executive Officer of Senesco. "We remain confident in our ability to

accomplish both of these goals."

revenues of $140,000 for the three month period ended December 31, 2009

consisted of a milestone payment in connection with an agricultural license

agreement. There was no revenue for the three month period ended December 31,

and development expenses during the three month period ended December 31, 2009

were $467,544, compared with $579,286 during the three month period ended

December 31, 2008, a decrease of 19.2%. The decrease was primarily

due to a decrease in the costs incurred in connection with our development of

SNS01 for multiple myeloma due to the timing of certain aspects of the

development and the cost of the research performed at the University of Waterloo

as a result of a decrease in the annual budget that began on September 1,

and administrative expenses were $685,409 for the three month period ended

December 31, 2009, compared with $649,056 during the three month period ended

December 31, 2008, an increase of 5.5%. This increase was due

primarily to a $58,000 increase in payroll and benefits, primarily the result of

the severance agreement with the Company's former President and CEO, and a

$17,000 increase in share-based compensation. These increases were partially

offset by a $64,000 decrease in investor relations costs; primarily the result

of the Company having not incurred the costs of holding its annual meeting for

the current year during this period, as it did in the corresponding period of

December 31, 2009, Senesco's cash balance totalled $751,787, with working

capital of $881,652, which the Company estimates will cover its expenses for

approximately the next two to three months from December 31, 2009.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger

or delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain diseases inflammatory and ischemic diseases.

Senesco takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of

1995. Actual results could differ materially from such statements

expressed or implied herein as a result of a variety of factors, including, but

not limited to: the ability of the Company to successfully transition to new

management; the ability of the Company to consummate additional financings; the

development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, the Company's

ability to meet its funding milestones under its financing transaction, the

Company's ability to comply with the continued listing standards of the AMEX, as

well as other factors expressed from time to time in the Company's periodic

filings with the Securities and Exchange Commission (the "SEC"). As a

result, this press release should be read in conjunction with the Company's

periodic filings with the SEC. The forward-looking statements

contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.

SENESCO TECHNOLOGIES, INC.

(A DEVELOPMENT STAGE

CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS